Tumor antigen specific iTreg accumulate in the tumor microenvironment and suppress therapeutic vaccination

Por Schreiber, Taylor H., Wolf, Dietlinde, Bodero, Maria, Podack, Eckhard
Publicado em 2012

The promise of CD4(+)FoxP3(+) regulatory T-cell manipulation in vivo: applications for allogeneic hematopoietic stem cell transplantation

Por Copsel, Sabrina, Wolf, Dietlinde, Komanduri, Krishna V., Levy, Robert B.
Publicado no Haematologica (2019)

T Cell Costimulation by TNFRSF4 and TNFRSF25 in the Context of Vaccination

Por Schreiber, Taylor H., Wolf, Dietlinde, Bodero, Maria, Gonzalez, Louis, Podack, Eckhard R.
Publicado em 2012

Induction of Fas Ligand Expression by HIV Involves the Interaction of Nef with the T Cell Receptor ζ Chain

Por Xu, Xiao-Ning, Laffert, Bernd, Screaton, Gavin R., Kraft, Michael, Wolf, Dietlinde, Kolanus, Waldemar, Mongkolsapay, Juthathip, McMichael, Andrew J., Baur, Andreas S.
Publicado em 1999

Therapeutic Treg expansion in mice by TNFRSF25 prevents allergic lung inflammation

Por Schreiber, Taylor H., Wolf, Dietlinde, Tsai, Matthew S., Chirinos, Jackie, Deyev, Vadim V., Gonzalez, Louis, Malek, Thomas R., Levy, Robert B., Podack, Eckhard R.
Publicado em 2010

Superior immune reconstitution using Treg-expanded donor cells versus PTCy treatment in preclinical HSCT models

Por Wolf, Dietlinde, Bader, Cameron S., Barreras, Henry, Copsel, Sabrina, Pfeiffer, Brent J., Lightbourn, Casey O., Altman, Norman H., Komanduri, Krishna V., Levy, Robert B.
Publicado no JCI Insight (2018)

Very Low Numbers of CD4(+)FoxP3(+) Tregs Expanded in Donors via TL1A-Ig and Low Dose IL-2 Exhibit a Distinct Activation / Functional Profile and Suppress GVHD in a Pre-clinical Mod...

Por Copsel, Sabrina, Wolf, Dietlinde, Kale, Brandon, Barreras, Henry, Lightbourn, Casey O., Bader, Cameron S., Alperstein, W., Altman, Norman H., Komanduri, Krishna V., Levy, Robert B.
Publicado no Biol Blood Marrow Transplant (2018)

Marked in vivo Donor Treg Expansion via IL-2 and TL1A-Ig stimulation ameliorates GVHD but preserves GVL in recipients post-HSCT

Por Wolf, Dietlinde, Barreras, Henry, Bader, Cameron S., Copsel, Sabrina, Lightbourn, Casey O., Pfeiffer, Brent J., Altman, Norman H., Podack, Eckhard R., Komanduri, Krishna V., Levy, Robert B.
Publicado no Biol Blood Marrow Transplant (2017)

Use of Post-transplant Cyclophosphamide Treatment to Build a Tolerance Platform to Prevent Liquid and Solid Organ Allograft Rejection

Por Lightbourn, Casey O., Wolf, Dietlinde, Copsel, Sabrina N., Wang, Ying, Pfeiffer, Brent J., Barreras, Henry, Bader, Cameron S., Komanduri, Krishna V., Perez, Victor L., Levy, Robert B.
Publicado no Front Immunol (2021)

STING differentially regulates experimental GVHD mediated by CD8 versus CD4 T cell subsets

Por Bader, Cameron S, Barreras, Henry, Lightbourn, Casey O, Copsel, Sabrina N, Wolf, Dietlinde, Meng, Jingjing, Ahn, Jeonghyun, Komanduri, Krishna V, Blazar, Bruce R, Jin, Lei, Barber, Glen N, Roy, Sabita, Levy, Robert B
Publicado no Sci Transl Med (2020)

BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT

Por Copsel, Sabrina N., Lightbourn, Casey O., Barreras, Henry, Lohse, Ines, Wolf, Dietlinde, Bader, Cameron S., Manov, John, Kale, Brandon J., Shah, Devangi, Brothers, Shaun P., Perez, Victor L., Komanduri, Krishna V., Wahlestedt, Claes, Levy, Robert B.
Publicado no Front Immunol (2019)